Thomas Hutson, DO, PharmD:For our particular patient who went on to receive lenvatinib/everolimus after sunitinib, at the point in which she has progression, I would consider strongly the use of immunotherapy as a third-line, leaving cabozantinib as a fourth-line option for her.
In summary, this patient’s case and unique characteristics provide us a snapshot into real-world management of intermediate-/poor-risk RCC. We see a patient who has multiple sites of disease, who gets started on traditional frontline therapy with sunitinib, has standard or less than standard response, and then moves on to second-line therapy with the combination of lenvatinib and everolimus.
I’ve discussed with you that alternative options, including nivolumab and cabozantinib, would also be considered, and in this particular patient would be employed in the third- and fourth-line setting.
Please understand that treatment options are changing rapidly in RCC. We need these options and we anxiously await the results of ongoing phase III trials. Our goal at the end of the day is to provide our patients with a longer survival, the greatest tolerability, and best quality of life.
Transcript edited for clarity.
A 70-Year-Old African-American Woman with Metastatic RCC
December 2017
June 2018
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
July 8th 2024During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
Read More